Q-omics provides the consensus-scored IGLL4P profile across patient tissues and cancer cell-line models. IGLL4P expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, IGLL4P is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, IGLL4P RNA expression shows 10,830 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ESCA, LUAD, and THYM as cancer lineages where IGLL4P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLL4P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLL4P survival associations across molecular data types. IGLL4P RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLL4P RNA expression–survival associations across cancer types. High IGLL4P expression shows unfavorable associations in STAD, BRCA and DLBC, but favorable associations in ESCA, HNSC and LUAD. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify ESCA as the clearest survival context for IGLL4P RNA expression.
This table summarizes IGLL4P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLL4P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLL4P shows lower tumor expression in LUAD and CHOL and higher tumor expression in HNSC. The LUAD box plot shows higher IGLL4P RNA expression in normal versus tumor tissue (log2 FC = −0.513, t-test p < 0.001).
This table shows molecular features associated with IGLL4P in patient tissues and cancer cell lines. In patient samples, IGLL4P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
